TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy of Amoxicillin Given Twice or Three Times a Day Among Children With Non-severe Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged between 2 and 59 months~* Report of respiratory complaints~* Presence of pulmonary infiltrate on chest x-ray taken on admission and read by the pediatrician on duty~Exclusion Criteria:~* lower chest indrawing~* danger signs (inability to drink, convulsions, somnolence, central cyanosis, grunting in a calm child)~* diagnosed underlying chronic diseases (anatomic abnormalities of the respiratory tract, chronic pulmonary illness besides asthma, immunological defects, progressing neurological disorders, psychomotor retardation, heart disease with clinical repercussion, hemoglobinopathy, liver or kidney disease)~* severe malnutrition~* other concurrent infection~* hospitalization during the previous 7 days~* amoxicillin or similar antibiotic use during the last 48 hours~* allergy to amoxicillin~* history of aspiration

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Amoxicillin given twice a day (Type: ACTIVE_COMPARATOR): None
- Amoxicillin given three times a day (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 70a~* Subjects understand study related activities and give written informed concent~* HbA1c between 7 - 10 % under treatment with premixed insulin (2-3 injections)~Exclusion Criteria:~* Females of child-bearing age~* History of hypoglycemia unawareness~* Gastrointestinal disease associated with prolonged nausea and vomiting~* Impaired liver function (transaminase \>2x than normal)~* Impaired kidney function (creatinin \> 1,2 mg/dl)~* Known intolerance against GLP-1 receptor agonists~* History of pancreatitis or pancreas tumor~* Malignancies, autoimmune diseases~* Severe dyslipidemia (serum triglycerides \> 400 mg/dl, cholesterol \> 300 mg/dl)~* Psychiatric disorder~* Oral glucose lowering medication except for metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): 10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis~Exclusion Criteria:~* previous H pylori-eradication therapy~* ingestion of antibiotics or bismuth within the prior 4 weeks~* patients with allergic history to the medications used~* patients with previous gastric surgery~* the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~* pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bismuth quadruple therapy (Type: EXPERIMENTAL): pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
- Hybrid therapy (Type: ACTIVE_COMPARATOR): (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Signed Written Informed Consent~* Subjects must have received at least one dose of Asunaprevir and/or Daclatasvir~* Subjects participating in Daclatasvir and/or Asunaprevir studies (ie, protocol numbers beginning with AI443, AI444 or AI447) may enroll regardless of virologic response~* Completed the required post-treatment follow-up period in previous study~* Must enroll in this study within 6 months of completing previous BMS study or within 6 months of protocol availability at the clinical site~* Men and women, ages 18 and older~Exclusion Criteria:~* Subject must not have been treated with any antiviral or immunomodulatory drug for chronic hepatitis C (CHC) after completion of the previous study during which Asunaprevir and/or Daclatasvir were administered~* Subject must not be participating in any other trial, excluding non-interventional trials~* Prisoners or subjects who are involuntarily incarcerated~* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with chronic hepatitis C (Type: None): Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Physician-diagnosed mild to moderate knee osteoarthritis (KL Grade 2-3) based on fixed-flexion x-ray radiological findings for osteophytes and joint space narrowing within the past 12 months~* Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA~* 45-85 years of age~* Report a frequent pain score between 3-7 (NRS range: 0-10) during the week preceding enrollment~* Report that knee pain negatively affects quality of life~* Willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound 1% diclofenac gel provided to the subject at the initiation of the study~* Deemed appropriate by their physician or by the study site physician to participate~Exclusion Criteria:~* Cannot successfully demonstrate the ability to put on and take off the device~* Display any condition which, in the judgment of the investigator, would make participation in the study unacceptable, including, but not limited to, the subject's ability to understand and follow instructions.~* Have severe OA or have little to no cartilage in the knee~* Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months~* Are non-ambulatory~* Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening~* Modify their medications during the course of the study (medications and doses must remain constant throughout the study)~* Currently taking steroids~* Have contraindication to radiograph~* Have a secondary cause of arthritis (metabolic or inflammatory)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Experimental: SAM ultrasound and diclofenac patch (Type: EXPERIMENTAL): Patients receive treatment from the SAM Ultrasonic Diathermy Device for 4 hours every day for 7 days combined with 1% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Triplication of glycine decarboxylase gene~Exclusion Criteria:~* Normal glycine decarboxylase copy number

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- glycine (Type: ACTIVE_COMPARATOR): Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
- Placebo (Type: PLACEBO_COMPARATOR): placebo, TID dosing, 6 weeks Double-blind
- glycine, open-label (Type: ACTIVE_COMPARATOR): glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peri- and postmenopausal women between the ages of 40 and 70 years, inclusive.~* A primary diagnosis of MDD, single or recurrent episode, without psychotic features using the modified International Neuropsychiatric Interview (MINI).~* Montgomery-Asberg Depression Rating Scale (MADRS) total score \> or = 22 at the screening and baseline visit.~Exclusion Criteria:~* Use of oral estrogen-, progestin-, androgen-, or Selective Estrogen Receptor Modulator (SERM)-containing drug products 8 weeks before baseline.~* Current (within 12 months) psychoactive substance abuse or dependence (including alcohol), manic episode, post-traumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder.~* A history or active presence of clinically important medical disease.~Additional criteria apply.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexmedetomidine on Nol-Index Guided Remifentanil Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- American Society of Anesthesiologists (ASA) grades 1-2 undergoing scheduled stomatological, cervical, and thyroid surgery anticipated to last at least two hours~Exclusion Criteria:~* ASA score \>2~* Preoperative organ dysfunction~* Patients with non-regular cardiac rhythm~* Implanted pacemakers~* Emergent surgery~* Pregnancy or lactation~* Allergy or intolerance to any of the study drugs~* Participation in another interventional study~* Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil Analgesia (Type: ACTIVE_COMPARATOR): Continuous intraoperative analgesia with remifenanil + 0.9% sodium chloride
- Remifentanil and Dexmedetomidine Analgesia (Type: ACTIVE_COMPARATOR): Continuous intraoperative analgesia with remifenanil + dexmedetomidine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) criteria for Bipolar I Disorder Most Recent Episode Manic or Mixed (with or without psychotic features)~* have a history of at least 2 previously documented mood episodes associated with Bipolar I Disorder (1 of which must be a manic or mixed episode) that required medical treatment within the past 3 years~* a total score of at least 20 on the YMRS at screening and at Day 1 of the study.~Exclusion Criteria:~* Meet DSM-IV criteria for any type of episode associated with bipolar disorder other than Bipolar I Disorder Most Recent Episode Manic or Mixed~* Meet DSM-IV criteria for rapid cycling~* Meet DSM-IV criteria for schizoaffective disorder~* Known or suspected borderline or antisocial personality disorder~* be, in the opinion of the investigator, at significant immediate risk for suicidal or violent behavior during the course of the study based on current status or prior history (e.g., suicide attempts during previous episodes).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone ER (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Olanzapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants between 8 months and 8 months plus two weeks of age;~2. Complete vaccination of national immunization schedule before 8 months;~3. Healthy infants;~4. Live in the study county with good compliance who can participate in the entire observation period.~Exclusion Criteria:~1. Previous history of measles, rubella, or JE;~2. Previously received vaccines containing measles/rubella or JE components;~3. Contraindications to the study vaccines;~4. Received blood products or immunosuppressive treatments within last 3 months;~5. Received any live attenuated vaccines within the last 4 weeks, or any inactivated vaccines within 2 weeks;~6. Guardian refuses to participate in the study.

- Gender: ALL
- Minimum Age: 8 Months
- Maximum Age: 9 Months
- Healthy Volunteers: t

Study Arms:
- MR and JE coadministration group (Type: EXPERIMENTAL): Infants aged 8 months are vaccinated measles-rubella combined vaccine (MR) and Japanese Encephalitis alive vaccine (JE) in different sites at same time.
- MR administration alone group (Type: ACTIVE_COMPARATOR): Infants aged 8 months are vaccinated measles-rubella combined vaccine alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* history of stable coronary disease~* complete coronary revascularization with PCI at least 1 month prior to recruitment~* sinus rhythm~* absence of anginal symptoms~Exclusion Criteria:~* resting heart rate \<60 beats per minute~* severe reduction of left ventricle ejection fraction (\<40%)~* coronary artery by-pass surgery~* myocardial infarction, stroke or cerebral transient ischemic attack within the previous 6 months~* implanted pacemaker, cardioverter, or defibrillator~* sick sinus syndrome~* sinoatrial block~* congenital long QT~* complete atrioventricular block

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivabradine group (Type: ACTIVE_COMPARATOR): Ivabradine 5 mg twice daily + standard medical therapy
- Control group (Type: OTHER): Standard medical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects who previously participated in study V87P1, but did not receive the booster dose on day 202~Exclusion Criteria:~* Pregnant or breastfeeding~* Receipt of another vaccine or any investigational agent within the past 4 weeks~* Surgery planned during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants 5 weeks of age (range: 35-41 days).~* Parents that consent for participation in the full length of the study.~* Parents that are able to understand and comply with planned study procedures.~Exclusion Criteria:~* Parents and infants who are unable to participate in the full length of the study.~* A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.~* A diagnosis or suspicion of bleeding disorder that would contraindicate parenteral administration of fIPV or collection of blood by venipuncture.~* Evidence of a chronic medical condition identified by a study medical officer during physical exam.~* Infection or illness at the enrolment visit (i.e., 5 weeks of age) that a study medical officer judges would prevent the start of study activities at 6 weeks of age (i.e., blood collection and vaccination).~* Receipt of any polio vaccine (OPV or IPV/fIPV) before enrolment based upon documentation or parental recall.~* Known allergy/sensitivity or reaction to polio vaccine, or its contents.~* Infants from multiple births. Infants from multiple births will be excluded because the infant(s) who is/are not enrolled would likely receive OPV through routine immunization and transmit vaccine poliovirus to the enrolled infant.~* Infants from premature births (\<37 weeks of gestation).

- Gender: ALL
- Minimum Age: 35 Days
- Maximum Age: 41 Days
- Healthy Volunteers: t

Study Arms:
- mOPV1 + fIPV 6 weeks (Type: ACTIVE_COMPARATOR): mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
- mOPV1 + fIPV 10 weeks (Type: ACTIVE_COMPARATOR): mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
- mOPV1 only (Type: ACTIVE_COMPARATOR): mOPV1 administered at 6, 10, and 14 weeks.
- bOPV only (Type: ACTIVE_COMPARATOR): bOPV administered at 6, 10, and 14 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-center 12-week Study of HMS5552 in T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male \& female, 40\~75 years old~2. T2DM patients，anti-hyperglycemic drug-naïve and on diet \& exercise for at least 3 months, or with glucose controlled by Metformin or α-glucosidase inhibitor alone~3. HbA1c 7.5\~10.5% at screening and pre-randomization~4. Fasting plasma glucose (FPG)7.0\~11.1 millimole/liter (mmol/L, local lab) at screening, and 7.0\~13.3 millimole/liter (mmol/L, central lab) at pre-randomization~5. BMI: 19\~30kg/m\^2 \& TG\<5.5mmol/L~Exclusion Criteria:~1. T1D，secondary DM, pre-DM~2. kidney diseases or eGFR MDRD\<60ml/min/1.73m\^2~3. unstable CVDs~4. liver diseases~5. mental or CNS diseases

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HMS5552 dose 1 (Type: EXPERIMENTAL): 75mgQD oral administration
- HMS5552 dose 2 (Type: EXPERIMENTAL): 100mgQD oral administration
- HMS5552 dose 3 (Type: EXPERIMENTAL): 50mgBID oral administration
- HMS5552 dose 4 (Type: EXPERIMENTAL): 75mgBID oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, BID/QD oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete